Enrolling patients in its coronavirus-induced lung damage treatment study - David Mazzo, CEO, Caladrius Biosciences Inc 00:00:00

Share On Facebook Share On Twitter

Caladrius Biosciences, Inc. (NASDAQ:CLBS) CEO David Mazzo tells Proactive the New Jersey-based clinical-stage biopharmaceutical company has begun its proof-of-concept study of its product candidate CLBS119 as a treatment for coronavirus-induced lung damage.

Recent Videos